BRVE Stock: Price, Earnings History and SEC Filings
Braveheart Bio, Inc. (BRVE) last traded at $21.51, up 1.51% on the latest session and up 6.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.51 against an analyst estimate of $-0.25, a miss of 904.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BRVE earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Sep 8, 2026 | $-2.51 | $-0.25 | -904.00% |
BRVE beat the analyst EPS estimate in 0 of its last 1 reported quarters. Source: Nasdaq.
Latest SEC filings for BRVE
Insider filing activity
BRVE insiders filed 14 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BRVE news
- Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026Oct 30, 2026 · finance.yahoo.com
- Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026Oct 30, 2026 · finance.yahoo.com
About Braveheart Bio, Inc.
Braveheart Bio, Inc. (BRVE) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.